



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.								
10/629,533	07/29/2003	Ronald J. Thompson	Thompson-10A	6052								
7590 Donald N. Halgren 35 Central St. Manchester, MA 01944		10/26/2007	<table border="1"><tr><td colspan="2">EXAMINER</td></tr><tr><td colspan="2">LANDSMAN, ROBERT S</td></tr><tr><td>ART UNIT</td><td>PAPER NUMBER</td></tr><tr><td>1647</td><td></td></tr></table>		EXAMINER		LANDSMAN, ROBERT S		ART UNIT	PAPER NUMBER	1647	
EXAMINER												
LANDSMAN, ROBERT S												
ART UNIT	PAPER NUMBER											
1647												
			<table border="1"><tr><td>MAIL DATE</td><td>DELIVERY MODE</td></tr><tr><td>10/26/2007</td><td>PAPER</td></tr></table>	MAIL DATE	DELIVERY MODE	10/26/2007	PAPER					
MAIL DATE	DELIVERY MODE											
10/26/2007	PAPER											

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/629,533	Applicant(s) THOMPSON, RONALD	
	Examiner Robert Landsman, Ph.D.	Art Unit 1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 October 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1647

DETAILED ACTION

1. Formal Matters

- A. The Amendment filed 10/11/07 has been entered into the record.
- B. Claims 1-4 are pending and are the subject of this Office Action.

2. Specification

- A. The objection to the specification is withdrawn in view of Applicants' amendments to the Brief Description of the Figures.

3. Claim Objections

- A. The objection to the claims has been withdrawn in view of Applicants' amendments.
- B. The specification is objected to since the Brief Description of Figure 7 should recite "stomach" instead of "stmach."
- C. Claims 1-4 are objected to since it is unclear if claim 1 is drawn to all three of stimulating, depleting AND blocking or if it is drawn to one of stimulating, depleting OR blocking.

4. Claim Rejections - 35 USC § 112, first paragraph - enablement

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

- A. Claims 1-4 remain rejected under 35 USC 112, first paragraph, for the reasons already of record on pages 2-3 of the Office Action mailed 6/11/07. Applicants argue that it is the inventor's belief that the specification is enabling. This argument has been considered, but is not deemed persuasive. First, as noted in the above statute under 35 USC 112, first paragraph,

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1647

The claims recite a method of reducing appetite in a mammal by one or all of three ways – stimulating Ghrelin release, depleting Ghrelin stores, blocking Ghrelin activity in the brain or bloodstream. Applicant has disclosed how Ghrelin would apparently act on the stomach and on appetite, which, based on Applicants' specification, seems to be well-known in the art (see Applicants' discussion of the prior art). However, Applicant is claiming stimulating, depleting and/or blocking Ghrelin. While it may be apparent from the discussion of the prior art that these mechanisms may reduce appetite, Applicant has not provided any "full, clear, concise and exact terms" of how to make and use the invention.

In In re Wands, 8USPQ2d, 1400 (CAFC 1988) page 1404, the factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

Applicant has not provided any discussion, guidance or working examples of how to stimulate Ghrelin release. It appears from the specification that all that is known is that Ghrelin regulates appetite. However, no means of stimulating this hormone are described. The issue is similar for depleting Ghrelin stores and blocking Ghrelin activity. The Applicant has not clearly and concisely demonstrated how to perform such a method. No guidance or working examples of any method of doing so, including any compounds that act on Ghrelin, is disclosed. Applicant's Figures only describe a general mechanism of drug absorption using only a hypothetical drug. Given this lack of guidance and working examples it would not be predictable to the artisan how to practice the claimed invention. Not only is no "best mode" described, but, respectfully, no mode is described except for a number of generalizations.

If the invention is truly novel, then the Applicant does deserve some breadth; however, at this point, the claims and specification have not satisfactorily enabled the invention. Though the prior art may not teach the claimed mechanism, that does not default patentability to the instant application in lack of an enabling specification.

5. Claim Rejections - 35 USC § 112, first paragraph – written description

A. Claims 1-4 remain rejected under 35 USC 112, first paragraph, for the reasons already of record on pages 3-4 of the Office Action mailed 6/11/07. Applicants argue that it is the inventor's belief that the specification is enabling. This argument has been considered, but is not deemed persuasive for the reasons discussed above under enablement.

Art Unit: 1647

6. Claim Rejections - 35 USC § 112, second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- A. Claims 1-2 remain objected to for the reasons already of record on page 4 of the Office Action mailed 6/11/07. Applicants have not amended the claims, nor addressed this argument.

7. Conclusion

- A. No claim is allowable.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (571) 272-0888. The examiner can normally be reached on M-F 10 AM – 7 PM (eastern).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Robert Landsman, Ph.D.
Primary Examiner
Art Unit 1647